Abstract
BackgroundAlthough Immune checkpoint inhibitors (ICI)-targeting therapies have revolutionized the treatment of cancer, several tumors do not respond to those therapies. Preclinical and clinical evidences suggest that STING is a promising...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
